- Home
- NU vs SIGA Comparison
NU vs SIGA Comparison
Compare NU & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NU | SIGA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8B | 223.8M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NU | SIGA |
|---|---|---|
| Price | $14.04 | $3.15 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.08 | N/A |
| AVG Volume (30 Days) | ★ 61.2M | 622.2K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | $180.93 | N/A |
| Revenue Next Year | $21.24 | $224.81 |
| P/E Ratio | $33.29 | ★ $24.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.20 | $2.83 |
| 52 Week High | $18.98 | $9.45 |
Technical Indicators
Market Signals| Indicator | NU | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 51.45 |
| Support Level | $13.34 | $2.92 |
| Resistance Level | $14.72 | $3.32 |
| Average True Range (ATR) | 0.48 | 0.14 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 19.72 | 57.14 |
Price Performance
Historical ComparisonAbout NU Nu Holdings Ltd.
Nu Holdings Ltd is a Brazilian financial technology firm that offers digital banking services. Its services include Retail credit, SME credit, Payments, Customer assets, Insurance brokerage, E-commerce marketplace, and Mobile virtual network operator. It operates in single operating segment and geographically it operates in Brazil, Mexico, and Other countries with the majority of revenue deriving from Brazil.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.